Four primary classes of medications form the cornerstone of HF therapy: angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors [32]. Here, SLC5A2 is linked to hydrops fetalis.